Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3345-3356

  Alukda, Dima ^a   Sturgis, Timothy ^a   Youan, Bi Botti C ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Coating; Colloids; Formulation; Functionalization; HIV prevention; Lipids; Nanoparticles; Tenofovir; Topical drug delivery

Indexed keywords

HEPARIN; MICROBICIDE; POLYLYSINE; SOLID LIPID NANOPARTICLE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ENCAPSULATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SYNTHESIS; ELECTRON MICROSCOPY; ENCAPSULATION; EPITHELIUM CELL; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; LIGHT SCATTERING; PARTICLE SIZE; STATISTICAL MODEL; ULTRAVIOLET SPECTROSCOPY; VAGINA EPITHELIUM; ZETA POTENTIAL;

EID: 79958792602     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22529     Document Type: Article

References (58)

1. UNAIDS 2008. 2008 Report on the global AIDS epidemic. Available at:. Access date: December 14th, 2010
2. Klasse PJ, Shattock R, Moore JP. 2008. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 59:455-471.
3. Balzarini J, van Damme L. 2007. Microbicide drug candidates to prevent HIV infection. Lancet 369(9563):787-797.
4. du Toit LC, Pillay V, Choonara YE. 2010. Nano-microbicides: Challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv Drug Deliv Rev 62(4-5):532-546.
5. Rohan LC, Sassi AB. 2009. Vaginal drug delivery systems for HIV prevention. AAPS J 11(1):78-87.
6. Garg AB, Nuttall J, Romano J. 2009. The future of HIV microbicides: Challenges and opportunities. Antivir Chem Chemother 19(4):143-150.
7. Vyas TK, Shah L, Amiji MM. 2006. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 3(5):613-628.
8. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. 2009. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 26(3):502-511.
9. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS. 2010. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 5(2):e9310 doi:10.1371/journal.pone.0009310.
10. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83(20):10358-10365.
11. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R Jr., Miller M. 2001. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses 17(12):1167-1173.
12. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R. 2008. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 5(8):e157; discussion e157.
13. Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC. 2009. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: Model of microbicide safety. J Infect Dis 200(4):599-608.
14. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47(2-3):165-196.
15. Almeida AJ, Souto E. 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59(6):478-490.
16. Wasan KM. 2009. The biological functions of lipid excipients and the implications for pharmaceutical products development. J Pharm Sci 98(2):379-382.
17. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, Yang Y, Xu H, Yang X. 2006. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 110(2):296-306.
18. Jayagopal A, Sussman EM, Shastri VP. 2008. Functionalized solid lipid nanoparticles for transendothelial delivery. IEEE Trans Nanobioscience 7(1):28-34.
19. Zilka A, Landau G, Hershkovitz O, Bloushtain N, Bar-Ilan A, Benchetrit F, Fima E, van Kuppevelt TH, Gallagher JT, Elgavish S, Porgador A. 2005. Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46. Biochemistry 44(44):14477-14485.
20. Higai K, Imaizumi Y, Suzuki C, Azuma Y, Matsumoto K. 2009. NKG2D and CD94 bind to heparin and sulfate-containing polysaccharides. Biochem Biophys Res Commun 386(4):709-714.
21. Ryser HJ, Drummond I, Shen WC. 1982. The cellular uptake of horseradish peroxidase and its poly(lysine) conjugate by cultured fibroblasts is qualitatively similar despite a 900-fold difference in rate. J Cell Physiol 113(1):167-178.
22. Ryser HJ, Shen WC. 1978. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci U S A 75(8):3867-3870.
23. Raboudi N, Julian J, Rohde LH, Carson DD. 1992. Identification of cell-surface heparin/heparan sulfate-binding proteins of a human uterine epithelial cell line (RL95). J Biol Chem 267(17):11930-11939.
24. Shen WC, Ryser HJ. 1981. Poly(L-lysine) has different membrane transport and drug-carrier properties when complexed with heparin. Proc Natl Acad Sci U S A 78(12):7589-7593.
25. Lai SK, Wang YY, Hanes J. 2009. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61(2):158-171.
26. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, Hanes J. 2007. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A 104(5):1482-1487.
27. Catalan JL, Lopez V, Perez P. 1995. Solvent dipolarity polarizability (SPP) of alcoholic solvents. Liebigs Ann 1995(5):793-795.
28. Decher G. 1997. Fuzzy nanoassemblies: Towars layered ploymeric multicomposites. Science 277:1232-1237.
29. Koppel DE. 1972. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: The method of cumulants. J Chem Phys 57:4814-4820.
30. Katzel U, Vorbau M, Stintz M, Gottschalk-Gaudig T, Barthel H. 2008. Dynamic light scattering for the characterization of polydisperse fractal systems: II. Relation between structure and DLS results. Part Part Syst Charact 25:19-30.
31. Kolchens S, Ramaswami V, Birgenheier J, Nett L, O'Brien DF. 1993. Quasi-elastic light scattering determination of the size distribution of extruded vesicles. Chem Phys Lipids 65(1):1-10.
32. Montgomery DC. 1995. Response surface methods and design in design and analysis of experiments. New York: John Wiley and sons, Inc., pp 405-458.
33. Patel SB, Baghel US, Rajesh P, Prabhakar D, Engla G, Nagar PN. Spectrophotometric method development and validation for simultaneous estimation of tenofovir disoproxil fumarate and emtricitabine in bulk drug and tablet dosage form. Int J Pharm Clin Res 1:28-30.
34. Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50(1):161-177.
35. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. 2007. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59(6):454-477.
36. Magenheim B, Benita S. 1996. The use of factorial design in the development of nanoparticulate dosage forms. In Microencapsulation, methods and industrial applications. New York: Marcel Dekker, pp 93-132.
37. Zhang T, Murowchick J, Youan BB. 2010. Optimization of formulation variables affecting spray-dried oily core nanocapsules by response surface methodology. J Pharm Sci. 100
38. Peng ZG, Hidajat K, Uddin MS. 2004. Adsorption of bovine serum albumin on nanosized magnetic particles. J Colloid Interface Sci 271(2):277-283.
39. Peters T Jr.. 1985. Serum albumin. Adv Protein Chem 37:161-245.
40. Estey T, Kang J, Schwendeman SP, Carpenter JF. 2006. BSA degradation under acidic conditions: A model for protein instability during release from PLGA delivery systems. J Pharm Sci 95(7):1626-1639.
41. Curvale R, Masuelli M, Padilla AP. 2008. Intrinsic viscosity of bovine serum albumin conformers. Int J Biol Macromol 42(2):133-137.
42. Richards LJ. 1993. Viscosity and the shapes of macromolecules: A physical chemistry experiment using molecular-level models in the interpretation of macroscopic data obtained from simple measurements. J Chem Educ 70(8): 685-689.
43. Harrington WF, Johnson P, Ottewill RH. 1956. Bovine serum albumin and its behaviour in acid solution. Biochem J 62(4):569-582.
44. Schubert MA, Muller-Goymann CC 2003. Solvent injection as a new approach for manufacturing lipid nanoparticles-Evaluation of the method and process parameters. Eur J Pharm Biopharm 55(1):125-131.
45. Wetzel R, Becker M, Behlke J, Billwitz H, Bohm S, Ebert B, Hamann H, Krumbiegel J, Lassmann G. 1980. Temperature behaviour of human serum albumin. Eur J Biochem 104(2):469-478.
46. Sjostrom B, Kaplun A, Talmon Y, Cabane B. 1995. Structures of nanoparticles prepared from oil-in-water emulsions. Pharm Res 12(1):39-48.
47. van Gelder J, Witvrouw M, Pannecouque C, Henson G, Bridger G, Naesens L, De Clercq E, Annaert P, Shafiee M, van Den Mooter G, Kinget R, Augustijns P. 1999. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. Int J Pharm 186(2):127-136.
48. Olbrich C, Gessner A, Kayser O, Muller RH. 2002. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 10(5):387-396.
49. Wong HL, Bendayan R, Rauth AM, Wu XY. 2004. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 93(8):1993-2008.
50. Sato K. 2001. Crystallization behaviour of fats and lipids-A review. Chem Eng Sci 56:2255-2265.
51. Suzanne M, Watt EA, Sue Armitage. 2007. Cryopreservation of hematopoietic stem/progenitor cells for therapeutic use. In Cryopreservation and freeze-drying protocols; Day JG, Stacey GN, Eds. 2nd ed. Totowa, New Jersey: Humana Press Inc., pp 237-259.
52. Bunjes H, Steiniger F, Richter W 2007. Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir 23:4005-4011.
53. Lederman MM, Offord RE, Hartley O. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 6(5):371-382.
54. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996):1168-1174.
55. Williams CM, Bateman PA, Jackson KG, Yaqoob P. 2003. 44th international conference on the bioscience of lipids. Oxford, UK: Keble College.
56. Takatori M, Kuroda Y, Hirose M. 2006. Local anesthetics suppress nerve growth factor-mediated neurite outgrowth by inhibition of tyrosine kinase activity of TrkA. Anesth Analg 102(2):462-467.
57. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. 2005. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49(5):1898-1906.
58. Sassi AB, Isaacs CE, Moncla BJ, Gupta P, Hillier SL, Rohan LC. 2008. Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci 97(8):3123-3139.